Early stage attraction

Biotechnology Value Fund wanted to own a piece of what the firm thinks is one of the few pure drug discovery platforms remaining in the industry and thus invested €30 million ($40.2 million) to get a slice of Evotec AG (Xetra:EVT).

According to the firm's Matthew Perry, an industry shift toward more product-focused business models has allowed Evotec to position itself as a drug discovery partner of choice...